Yamashita, Yugo
Morimoto, Takeshi
Kadota, Kazushige
Takase, Toru
Hiramori, Seiichi
Kim, Kitae
Oi, Maki
Akao, Masaharu
Kobayashi, Yohei
Toyofuku, Mamoru
Inoko, Moriaki
Tada, Tomohisa
Chen, Po-Min
Murata, Koichiro
Tsuyuki, Yoshiaki
Nishimoto, Yuji
Sakamoto, Jiro
Togi, Kiyonori
Mabuchi, Hiroshi
Takabayashi, Kensuke
Kato, Takao
Ono, Koh
Kimura, Takeshi
Article History
Received: 31 May 2022
Accepted: 22 December 2022
First Online: 23 December 2022
Competing interests
: Dr. Yamashita received lecture fees from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, and Bayer Healthcare. Dr Morimoto reports lecturer's fees from Bristol-Myers Squibb, Daiichi Sankyo, Japan Lifeline, Kowa, Kyocera, Novartis, and Toray; manuscript fees from Bristol-Myers Squibb and Kowa; advisory board for Sanofi. Dr. Akao received lecture fees from Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim, Bayer Healthcare and Daiichi-Sankyo. Dr. Nishimoto received lecture fees from Daiichi-Sankyo, Bristol-Myers Squibb, Pfizer, and Bayer Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.